MET and non-small cell lung carcinoma: The forced over-expression of miR-19a promotes EMT [199], reduces survival in NSCLC patients [145], and increases gefitinib-resistance in NSCLC cells via directly targeting the c-MET gene, both in in vivo and in vitro experimental systems [109].